|Table of Contents|

Expression of CSPG4 in gastrointestinal stromal tumor and its relationship with clinical parameters and tumor immune cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 09
Page:
1683-1686
Research Field:
Publishing date:

Info

Title:
Expression of CSPG4 in gastrointestinal stromal tumor and its relationship with clinical parameters and tumor immune cells
Author(s):
ZHANG Xianglian1; WANG Xingfen1; WANG Zhiqiang2; LIANG Rui1
1.Department of Pathology;2.Department of Anorectal Surgery,Second Hospital of Tianjin Medical University,Tianjin 300211,China.
Keywords:
chondroitin sulfate proteoglycan 4; gastrointestinal stromal tumor; tumor-infiltrating lymphocytes; tumor microenvironment
PACS:
R735
DOI:
10.3969/j.issn.1672-4992.2023.09.018
Abstract:
Objective:To investigate the expression of chondroitin sulfate proteoglycan 4 (CSPG4) in gastrointestinal stromal tumor (GIST),and its correlation with clinicopathological parameters and immune cells.Methods:The expression of CSPG4 protein in 162 GIST cases was measured by immunohistochemistry with EnVision,and the correlation with age,gender,site of occurrence and NIH risk grade was analyzed.The relationship between the expression of CSPG4 protein in GIST and the CD4+,CD8+,CD20+,CD56+ and CD68+ cell counts in tumor-infiltrating lymphocytes (TILs) was also investigated.Results:The expression of CSPG4 protein in GIST was correlated with the site of occurrence and NIH risk grade (P＜0.05),and wasn' t correlated with age and gender (P>0.05).The expression of CSPG4 protein in GIST was correlated with CD8+,CD56+ and CD68+ cell counts (P＜0.05),and wasn' t correlated with CD4+ and CD20+ cells (P>0.05).Conclusion:The expression level of CSPG4 protein can partly predict the biological behavior of GIST,and CSPG4 protein may participate in the development of GIST by regulating the tumor immune microenvironment.

References:

［1］HEMMING ML,HEINRICH MC,BAUER S,et al.Translational insights into gastrointestinal stromal tumor and current clinical advances［J］.Ann Oncol,2018,29(10):2037-2045．
［2］AKAHOSHI K,OYA M,KOGA T,et al.Current clinical management of gastrointestinal stromal tumor［J］.World J Gastroenterol,2018,24(26):2806-2817．
［3］FARAG S,SMITH MJ,FOTIADIS N,et al.Revolutions in treatment options in gastrointestinal stromal tumours（GISTs):the latest updates［J］.Curr Treat Options Oncol,2020,21(7):55-65.
［4］林晨,张再重,王烈.胃肠间质瘤诊断和治疗进展［J］.肿瘤防治研究,2022,49(01):1-4. LIN C,ZHANG ZC,WANG L.Progress in the diagnosis and treatment of gastrointestinal stromal tumors ［J］.Cancer Prevention and Treatment Research,2022,49(01):1-4.
［5］MARTA M,CRISTINA C,CRISTIANO C,et al.Chondroitin sulphate proteoglycans in the tumour microenvironment［J］.Adv Exp Med Biol,2020,1272:73-92.
［6］WADE A,ROBINSON AE,ENGLER JR,et al．Proteoglycans and their roles in brain cancer［J］.FEBS J,2013,280(10):2399-2417.
［7］NICOLOSI PA,DALLATOMASINA A,PERRIS R．Theranostic impact of NG2/CSPG4 proteoglycan in cancer［J］.Theranostics,2015,5(5):530-544.
［8］AMPOFO E,SCHMITT BM,MENGER MD,et al．The regulatory mechanisms of NG2/CSPG4 expression［J］.Cell Mol Biol Lett,2017,22(1):4.
［9］ROLIH V,BARUTELLO G,IUSSICH S,et al.CSPG4:a prototype oncoantigen for translational immunotherapy studies［J］.J Transl Med,2017,15(1):151-165.
［10］GELDRES C,SAVOLDO B,HOYOS V,et al.T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo［J］.Clin Cancer Res,2014,20(4):962-971.
［11］VALLILAS C,SARANTIS P,KYRIAZOGLOU A,et al.Gastrointestinal stromal tumors (GISTs):Novel therapeutic strategies with immunotherapy and small molecules［J］.Int J Mol Sci,2021,22(2):493.
［12］CAMPOLI M,FERRONE S,WANG X.Functional and clinical relevance of chondroitin sulfate proteoglycan 4［J］.Adv Cancer Res,2010,109:73-121.
［13］SONG YX,DU YQ,QIN CP,et al.Gemcitabine-resistant biomarkers in bladder cancer are associated with tumor-immune microenvironment［J］.Front Cell Dev Biol,2022,9:809620.
［14］CAITLIN E,DESSISLAVA S,ADNAN A,et al.CSPG4 is a potential therapeutic target in anaplastic thyroid cancer［J］.Thyroid,2021,33(12):539-540.
［15］SCHIFFER D,ANNOVAZZI L,BOVIO E,et al.NG2 proteoglycan in the diagnosis,prognosis and therapy of gliomas［J］.Int J Cell Sci & Mol Biol,2017,2(2):555582.
［16］YANG JB,LIAO QJ,MATTHEW P,et al.Chondroitin sulfate proteoglycan 4,a targetable oncoantigen that promotes ovarian cancer growth,invasion,cisplatin resistance and spheroid formation［J］.Transl Oncol,2022,16:101318.
［17］HU ZY,ZHENG CJ,YANG JB,et al.Co-expression and combined prognostic value of CSPG4 and PDL1 in TP53-aberrant triple-negative breast cancer［J］.Front Oncol,2022,12:804466.
［18］KAROLINA U,MAHZEIAR S,TANJA K,et al.A chondroitin sulfate proteoglycan 4 specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model［J］.Int J Oncol,2021,59(3):70.
［19］ALEXANDRE DN,PASCAL F,MAELLE P,et al.CSPG4 expression in GIST is associated with better prognosis and strong cytotoxic immune response［J］.Cancers (Basel),2022,14(5):1306.
［20］RUSAKIEWICZ S,SEMERARO M,SARABI M,et al.Immune in filtrates are prognostic factors in localized gastrointestinal stromal tumors［J］.Cancer Res,2013,73(12):3499-3510.

Memo

Memo:
天津市科技计划项目(编号:21JCYBJC01730)
Last Update: 2023-03-30